

John R Hurst

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5863575/publications.pdf>

Version: 2024-02-01

235
papers

15,548
citations

30070

54
h-index

19190

118
g-index

256
all docs

256
docs citations

256
times ranked

13957
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. <i>Gut</i> , 2022, 71, 415-423.	12.1	28
2	Does pay-for-performance improve patient outcomes in acute exacerbation of COPD admissions?. <i>Thorax</i> , 2022, 77, 239-246.	5.6	5
3	Risk for development of active tuberculosis in patients with chronic airway disease—a systematic review of evidence. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2022, 116, 390-398.	1.8	3
4	Acceptability of hygiene, face covering and social distancing interventions to prevent exacerbations in people living with airways diseases. <i>Thorax</i> , 2022, 77, 505-507.	5.6	9
5	Discriminative Accuracy of Chronic Obstructive Pulmonary Disease Screening Instruments in 3 Low- and Middle-Income Country Settings. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 151.	7.4	31
6	Predictive Factors for and Complications of Bronchiectasis in Common Variable Immunodeficiency Disorders. <i>Journal of Clinical Immunology</i> , 2022, 42, 572-581.	3.8	5
7	Upper airway symptoms and Small Airways Disease in Chronic Obstructive Pulmonary Disease, COPD. <i>Respiratory Medicine</i> , 2022, 191, 106710.	2.9	4
8	Development, deployment and evaluation of digitally enabled, remote, supported rehabilitation for people with long COVID-19 (Living With COVID-19 Recovery): protocol for a mixed-methods study. <i>BMJ Open</i> , 2022, 12, e057408.	1.9	14
9	A clinical review of long-COVID with a focus on the respiratory system. <i>Current Opinion in Pulmonary Medicine</i> , 2022, 28, 174-179.	2.6	25
10	Development of a core outcome set for multimorbidity trials in low/middle-income countries (COSMOS): study protocol. <i>BMJ Open</i> , 2022, 12, e051810.	1.9	6
11	NEWS2 as an Objective Assessment of Hospitalised COPD Exacerbation Severity. <i>International Journal of COPD</i> , 2022, Volume 17, 763-772.	2.3	4
12	Nasal and systemic inflammation in Chronic Obstructive Pulmonary Disease (COPD). <i>Respiratory Medicine</i> , 2022, 195, 106774.	2.9	8
13	Cardiovascular outcomes in patients with COPD-OSA overlap syndrome: A systematic review and meta-analysis. <i>Sleep Medicine Reviews</i> , 2022, 63, 101627.	8.5	13
14	Cost-Accuracy Analysis of Chronic Obstructive Pulmonary Disease Screening in Low- and Middle-Income Countries. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 353-356.	5.6	1
15	Multiple-Breath Washout Outcome Measures in Adults with Bronchiectasis. <i>Annals of the American Thoracic Society</i> , 2022, 19, 1489-1497.	3.2	3
16	Quality Standard Position Statements for Health System Policy Changes in Diagnosis and Management of COPD: A Global Perspective. <i>Advances in Therapy</i> , 2022, 39, 2302-2322.	2.9	5
17	The extremely preterm young adult — State of the art. <i>Seminars in Fetal and Neonatal Medicine</i> , 2022, 27, 101365.	2.3	2
18	Predictive modeling of COPD exacerbation rates using baseline risk factors. <i>Therapeutic Advances in Respiratory Disease</i> , 2022, 16, 175346662211073.	2.6	10

#	ARTICLE	IF	CITATIONS
19	Size at birth, growth trajectory in early life, and cardiovascular and metabolic risks in early adulthood: EPICure study. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2021, 106, 149-155.	2.8	18
20	Gaps in COPD Guidelines of Low- and Middle-Income Countries. Chest, 2021, 159, 575-584.	0.8	41
21	A Patient Charter for Chronic Obstructive Pulmonary Disease. Advances in Therapy, 2021, 38, 11-23.	2.9	16
22	“Long-COVID™”: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax, 2021, 76, 396-398.	5.6	636
23	Specialty COPD care during COVID-19: patient and clinician perspectives on remote delivery. BMJ Open Respiratory Research, 2021, 8, e000817.	3.0	37
24	Development and Validity Assessment of a Chronic Obstructive Pulmonary Disease Knowledge Questionnaire in Low- and Middle-Income Countries. Annals of the American Thoracic Society, 2021, 18, 1298-1305.	3.2	2
25	A double-blind randomised controlled trial of protein supplementation to enhance exercise capacity in COPD during pulmonary rehabilitation: a pilot study. ERJ Open Research, 2021, 7, 00077-2021.	2.6	6
26	BronchUK: protocol for an observational cohort study and biobank in bronchiectasis. ERJ Open Research, 2021, 7, 00775-2020.	2.6	4
27	Effectiveness of low-dose theophylline for the management of biomass-associated COPD (LODOT-BCOPD): study protocol for a randomized controlled trial. Trials, 2021, 22, 213.	1.6	4
28	Operational Modeling with Health Economics to Support Decision Making for COPD Patients. Health Services Research, 2021, 56, 1271-1280.	2.0	5
29	Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet, The, 2021, 397, 928-940.	13.7	176
30	Remote Assessment of Lung Disease and Impact on Physical and Mental Health (RALPMH): Protocol for a Prospective Observational Study. JMIR Research Protocols, 2021, 10, e28873.	1.0	10
31	The high mental health burden of “Long COVID” and its association with on-going physical and respiratory symptoms in all adults discharged from hospital. European Respiratory Journal, 2021, 57, 2004364.	6.7	62
32	Treatment Strategies for GLILD in Common Variable Immunodeficiency: A Systematic Review. Frontiers in Immunology, 2021, 12, 606099.	4.8	24
33	A Systematic Literature Review of the Humanistic Burden of COPD. International Journal of COPD, 2021, Volume 16, 1303-1314.	2.3	26
34	The Impact of Re-Admissions in COPD. Archivos De Bronconeumologia, 2021, 58, 109-110.	0.8	2
35	Upper airway symptoms associate with the eosinophilic phenotype of COPD. ERJ Open Research, 2021, 7, 00184-2021.	2.6	5
36	Editorial: Interstitial Lung Disease in Primary Immunodeficiencies. Frontiers in Immunology, 2021, 12, 699126.	4.8	2

#	ARTICLE	IF	CITATIONS
37	Challenges in the Implementation of Chronic Obstructive Pulmonary Disease Guidelines in Low- and Middle-Income Countries: An Official American Thoracic Society Workshop Report. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1269-1277.	3.2	27
38	The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1467-1478.	10.7	84
39	Addressing a system failure to diagnose COPD and asthma. <i>Lancet Respiratory Medicine</i> , 2021, 9, 814-816.	10.7	0
40	Reduction in hospitalised COPD exacerbations during COVID-19: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2021, 16, e0255659.	2.5	90
41	CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care. <i>International Journal of COPD</i> , 2021, Volume 16, 2301-2322.	2.3	9
42	Research priorities for exacerbations of COPD. <i>Lancet Respiratory Medicine</i> , 2021, 9, 824-826.	10.7	28
43	ROSE: radiology, obstruction, symptoms and exposure – a Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working Group. <i>ERJ Open Research</i> , 2021, 7, 00399-2021.	2.6	19
44	An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1251-1258.	5.6	121
45	Strategies for the prevention, diagnosis and treatment of COPD in low- and middle- income countries: the importance of primary care. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1563-1577.	2.5	17
46	COVID-19 and “basal” exacerbation frequency in COPD. <i>Thorax</i> , 2021, 76, 432-433.	5.6	9
47	Pulmonary rehabilitation for COPD: A narrative review and call for further implementation in Saudi Arabia. <i>Annals of Thoracic Medicine</i> , 2021, 16, 299.	1.8	12
48	Research priorities to address the global burden of chronic obstructive pulmonary disease (COPD) in the next decade. <i>Journal of Global Health</i> , 2021, 11, 15003.	2.7	18
49	Predictors of 30- and 90-Day COPD Exacerbation Readmission: A Prospective Cohort Study. <i>International Journal of COPD</i> , 2021, Volume 16, 2769-2781.	2.3	22
50	Home monitoring of physiology and symptoms to detect interstitial lung disease exacerbations and progression: a systematic review. <i>ERJ Open Research</i> , 2021, 7, 00441-2021.	2.6	12
51	Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1275-1287.	10.7	394
52	Overcoming Therapeutic Inertia to Reduce the Risk of COPD Exacerbations: Four Action Points for Healthcare Professionals. <i>International Journal of COPD</i> , 2021, Volume 16, 3009-3016.	2.3	3
53	Granulomatous “lymphocytic interstitial lung disease: an international research prioritisation. <i>ERJ Open Research</i> , 2021, 7, 00467-2021.	2.6	6
54	Application of oxygen saturation variability analysis for the detection of exacerbation in individuals with COPD: A proof-of-concept study. <i>Physiological Reports</i> , 2021, 9, e15132.	1.7	9

#	ARTICLE	IF	CITATIONS
55	The clinical utility of forced oscillation technique during hospitalisation in patients with exacerbation of COPD. ERJ Open Research, 2021, 7, 00448-2021.	2.6	2
56	Telehealth for patients with interstitial lung diseases (ILD): results of an international survey of clinicians. BMJ Open Respiratory Research, 2021, 8, e001088.	3.0	11
57	COPD Exacerbations: A Patient and Physician's Perspective. Advances in Therapy, 2020, 37, 10-16.	2.9	6
58	Disease Progression Modeling in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 294-302.	5.6	56
59	National clinical audit for hospitalised exacerbations of COPD. ERJ Open Research, 2020, 6, 00208-2020.	2.6	15
60	Pneumonia in exacerbations of COPD: what is the clinical significance?. ERJ Open Research, 2020, 6, 00282-2019.	2.6	8
61	Managing Granulomatous "Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders: e-GLILDnet International Clinicians Survey. Frontiers in Immunology, 2020, 11, 606333.	4.8	10
62	British Thoracic Society survey of rehabilitation to support recovery of the post-COVID-19 population. BMJ Open, 2020, 10, e040213.	1.9	29
63	<p>A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD</p>. International Journal of COPD, 2020, Volume 15, 3093-3103.	2.3	0
64	<p>Thoracic Imaging at Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review</p>. International Journal of COPD, 2020, Volume 15, 1751-1787.	2.3	5
65	Enrichment of the airway microbiome in people living with HIV with potential pathogenic bacteria despite antiretroviral therapy. EClinicalMedicine, 2020, 24, 100427.	7.1	4
66	Illness representations of chronic obstructive pulmonary disease (COPD) to inform health education strategies and research design "learning from rural Uganda. Health Education Research, 2020, 35, 258-269.	1.9	5
67	New developments in respiratory medicine: a primary immunodeficiency perspective. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 549-556.	2.3	0
68	Critical review of multimorbidity outcome measures suitable for low-income and middle-income country settings: perspectives from the Global Alliance for Chronic Diseases (GACD) researchers. BMJ Open, 2020, 10, e037079.	1.9	25
69	Caring for patients with COPD and COVID-19: a viewpoint to spark discussion. Thorax, 2020, 75, 1035-1039.	5.6	15
70	<p>A Novel Case-Finding Instrument for Chronic Obstructive Pulmonary Disease in Low- and Middle-Income Country Settings</p>. International Journal of COPD, 2020, Volume 15, 2769-2777.	2.3	12
71	Correction to: "We can't carry the weight of the whole world" Illness experiences among Peruvian older adults with symptoms of depression and anxiety. International Journal of Mental Health Systems, 2020, 14, .	2.7	0
72	Risk factors and associated outcomes of hospital readmission in COPD: A systematic review. Respiratory Medicine, 2020, 173, 105988.	2.9	40

#	ARTICLE	IF	CITATIONS
73	COPD exacerbation phenotypes in a real-world five year hospitalisation cohort. <i>Respiratory Medicine</i> , 2020, 167, 105979.	2.9	10
74	Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2020, 15, e0233147.	2.5	605
75	The effect of HIV status on the frequency and severity of acute respiratory illness. <i>PLoS ONE</i> , 2020, 15, e0232977.	2.5	6
76	The challenges of deploying artificial intelligence models in a rapidly evolving pandemic. <i>Nature Machine Intelligence</i> , 2020, 2, 298-300.	16.0	45
77	Risk factors for all-cause hospital readmission following exacerbation of COPD: a systematic review and meta-analysis. <i>European Respiratory Review</i> , 2020, 29, 190166.	7.1	87
78	<p>Adequacy of Therapy for People with Both COPD and Heart Failure in the UK: Historical Cohort Study</p>. <i>Journal of Pragmatic and Observational Research</i> , 2020, Volume 11, 55-66.	1.5	3
79	<p>Efficacy and Safety of LAMA/LABA Fixed-Dose Combination Therapies in Chronic Obstructive Pulmonary Disease: A Systematic Review of Direct and Indirect Treatment Comparisons</p>. <i>International Journal of COPD</i> , 2020, Volume 15, 1529-1543.	2.3	7
80	Relationship of CT densitometry to lung physiological parameters and health status in alpha-1 antitrypsin deficiency: initial report of a centralised database of the NIHR rare diseases translational research collaborative. <i>BMJ Open</i> , 2020, 10, e036045.	1.9	3
81	Nutritional supplementation during pulmonary rehabilitation in COPD: A systematic review. <i>Chronic Respiratory Disease</i> , 2020, 17, 147997312090495.	2.4	22
82	Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life. <i>European Journal of Internal Medicine</i> , 2020, 73, 1-6.	2.2	67
83	Chronic obstructive pulmonary disease: aetiology, pathology, physiology and outcome. <i>Medicine</i> , 2020, 48, 328-332.	0.4	0
84	Respiratory and Cardiovascular Outcomes in Survivors of Extremely Preterm Birth at 19 Years. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 422-432.	5.6	67
85	Interstitial lung disease in primary immunodeficiency: towards a brighter future. <i>European Respiratory Journal</i> , 2020, 55, 2000089.	6.7	10
86	Global Burden of COPD. , 2020, , 1-20.		4
87	Non-invasive testing for liver pathology in alpha-1 antitrypsin deficiency. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000820.	3.0	5
88	Multimorbidity: Not Just for the West. <i>Global Heart</i> , 2020, 15, 45.	2.3	8
89	Evidence-implementation gaps in low- and middle-income countries' COPD guidelines. , 2020, , .		0
90	Once Daily Versus Overnight and Symptom Versus Physiological Monitoring to Detect Exacerbations of Chronic Obstructive Pulmonary Disease: Pilot Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2020, 8, e17597.	3.7	18

#	ARTICLE	IF	CITATIONS
91	Predictive modelling of COPD exacerbation rates using baseline risk factors. , 2020, , .		0
92	Upper Respiratory Symptoms in Patients with Chronic Obstructive Pulmonary Disease. , 2020, , .		0
93	The effect of HIV status on the frequency and severity of acute respiratory illness. , 2020, 15, e0232977.		0
94	The effect of HIV status on the frequency and severity of acute respiratory illness. , 2020, 15, e0232977.		0
95	The effect of HIV status on the frequency and severity of acute respiratory illness. , 2020, 15, e0232977.		0
96	The effect of HIV status on the frequency and severity of acute respiratory illness. , 2020, 15, e0232977.		0
97	What is a COPD-Like Spirometry Test Result in Resource Constrained Settings?. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2019, 16, 213-214.	1.6	1
98	Pulmonary rehabilitation, physical activity and aortic stiffness in COPD. Respiratory Research, 2019, 20, 166.	3.6	10
99	Building toolkits for COPD exacerbations: lessons from the past and present. Thorax, 2019, 74, 898-905.	5.6	34
100	<p>Global use, utility, and methods of tele-health in COPD: a health care provider survey</p>. International Journal of COPD, 2019, Volume 14, 1713-1719.	2.3	15
101	Outcome measures in a combined exercise rehabilitation programme for adults with COPD and chronic heart failure: A preliminary stakeholder consensus event. Chronic Respiratory Disease, 2019, 16, 147997311986795.	2.4	6
102	Use, utility and methods of telehealth for patients with COPD in England and Wales: a healthcare provider survey. BMJ Open Respiratory Research, 2019, 6, e000345.	3.0	15
103	British Thoracic Society Guideline for bronchiectasis in adults. Thorax, 2019, 74, 1-69.	5.6	291
104	Imaging of Bronchial Pathology in Antibody Deficiency: Data from the European Chest CT Group. Journal of Clinical Immunology, 2019, 39, 45-54.	3.8	32
105	Airway microbiome in adult survivors of extremely preterm birth: the EPICure study. European Respiratory Journal, 2019, 53, 1801225.	6.7	20
106	Reply to Lan and Shi: Different Background, Short Duration, and Inappropriate Participants May Harm Your Conclusion. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 390-392.	5.6	1
107	Assessment of Treatment Response in Granulomatous Lymphocytic Interstitial Lung Disease (GLILD). , 2019, , .		1
108	Urban-Rural Disparities in Chronic Obstructive Pulmonary Disease Management and Access in Uganda. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2019, 6, 17-28.	0.7	18

#	ARTICLE	IF	CITATIONS
109	COPD and emphysema. , 2019, , 324-331.		0
110	Late Breaking Abstract - Arterial Stiffness and Cardiovascular Risk in hospitalised COPD patients. , 2019, , .		0
111	Nutritional Supplementation during Pulmonary Rehabilitation in Stable Chronic Obstructive Pulmonary Disease: A Systematic Review. , 2019, , .		0
112	Patient pathway modelling using Discrete Event Simulation to reduce readmissions in COPD. , 2019, , .		1
113	Reproducibility of an airway tapering measurement in computed tomography with application to bronchiectasis. Journal of Medical Imaging, 2019, 6, 1.	1.5	1
114	The National COPD Audit “ what you need to know. Clinical Medicine, 2019, 19, 499-502.	1.9	3
115	COPD exacerbations: transforming outcomes through research. Lancet Respiratory Medicine,the, 2018, 6, 172-174.	10.7	3
116	Pulmonary rehabilitation for patients with COPD during and after an exacerbation-related hospitalisation: back to the future?. European Respiratory Journal, 2018, 51, 1702577.	6.7	4
117	Chronic Obstructive Pulmonary Disease as a Risk Factor for Cardiovascular Disease. A View from the SUMMIT. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 2-4.	5.6	11
118	Respiratory Infections and Antibiotic Usage in Common Variable Immunodeficiency. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 159-168.e3.	3.8	46
119	Validation of the Saint George’s Respiratory Questionnaire in Uganda. BMJ Open Respiratory Research, 2018, 5, e000276.	3.0	10
120	Global Alliance for Chronic Disease researchers' statement on multimorbidity. The Lancet Global Health, 2018, 6, e1270-e1271.	6.3	43
121	Cardiovascular disease and COPD: dangerous liaisons?. European Respiratory Review, 2018, 27, 180057.	7.1	187
122	Effectiveness-implementation of COPD case finding and self-management action plans in low- and middle-income countries: global excellence in COPD outcomes (GECO) study protocol. Trials, 2018, 19, 571.	1.6	26
123	Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis. International Journal of COPD, 2018, Volume 13, 781-792.	2.3	19
124	Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 329-339.	5.6	196
125	The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions. European Respiratory Journal, 2018, 52, 1800328.	6.7	138
126	Consolidation and Exacerbation of COPD. Medical Sciences (Basel, Switzerland), 2018, 6, 44.	2.9	8

#	ARTICLE	IF	CITATIONS
127	Gastroesophageal Reflux Disease (GERD) and COPD. , 2018, , 165-174.		1
128	Tapering analysis of airways with bronchiectasis. , 2018, , .		4
129	Disease progression patterns in COPD. , 2018, , .		1
130	Persistent blood eosinophilia and COPD exacerbation risk after ICS withdrawal from triple therapy in the SUNSET study. , 2018, , .		1
131	Airway tapering in bronchiectatic and healthy airways. , 2018, , .		0
132	Late Breaking Abstract - Characteristics and treatment of patients with comorbid COPD and heart failure. , 2018, , .		0
133	Impact of Physical Frailty on Pulmonary Rehabilitation and Hospitalisation in COPD. , 2018, , .		0
134	Cardiovascular risk and exercise capacity in COPD. , 2018, , .		0
135	A randomised crossover trial investigating the effect of a portable positive pressure ventilation device on exercise tolerance in patients with COPD. , 2018, , .		0
136	Investigation of shortened lung clearance index (LCI) in the Bronch-UK Clinimetrics study.. , 2018, , .		0
137	Dyspnoea perception and susceptibility to exacerbation in COPD. Thorax, 2017, 72, 107-108.	5.6	2
138	Bronchiectasis and the risk of cardiovascular disease: a population-based study. Thorax, 2017, 72, 161-166.	5.6	60
139	Pulmonary Lobe Segmentation With Probabilistic Segmentation of the Fissures and a Groupwise Fissure Prior. IEEE Transactions on Medical Imaging, 2017, 36, 1650-1663.	8.9	28
140	The heterogeneity of systemic inflammation in bronchiectasis. Respiratory Medicine, 2017, 127, 33-39.	2.9	58
141	Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation. JAMA - Journal of the American Medical Association, 2017, 317, 2177.	7.4	443
142	British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 938-945.	3.8	138
143	Management of COPD exacerbations: aÂEuropean Respiratory Society/American Thoracic Society guideline. European Respiratory Journal, 2017, 49, 1600791.	6.7	438
144	How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 139-149.	5.6	68

#	ARTICLE	IF	CITATIONS
145	Multi-level Multi-task Structured Sparse Learning for Diagnosis of Schizophrenia Disease. Lecture Notes in Computer Science, 2017, 10435, 46-54.	1.3	1
146	Susceptibility to exacerbation in COPD. Lancet Respiratory Medicine, the, 2017, 5, e29.	10.7	21
147	Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. European Respiratory Journal, 2017, 50, 1602265.	6.7	131
148	One-off Spirometry Is Insufficient to Rule In or Rule Out Mild to Moderate Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 254-256.	5.6	0
149	Correlates and assessment of excess cardiovascular risk in bronchiectasis. European Respiratory Journal, 2017, 50, 1701127.	6.7	23
150	Effect of time and day of admission on hospital care quality for patients with chronic obstructive pulmonary disease exacerbation in England and Wales: single cohort study. BMJ Open, 2017, 7, e015532.	1.9	4
151	Pulmonary rehabilitation and cardiovascular risk in COPD: a systematic review. COPD Research and Practice, 2017, 3, .	0.7	4
152	Monitoring of Physiological Parameters to Predict Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review. Journal of Clinical Medicine, 2016, 5, 108.	2.4	54
153	Recording of hospitalizations for acute exacerbations of COPD in UK electronic health care records. Clinical Epidemiology, 2016, Volume 8, 771-782.	3.0	65
154	Update on alpha-1 antitrypsin deficiency: New therapies. Journal of Hepatology, 2016, 65, 413-424.	3.7	66
155	Chronic obstructive pulmonary disease: aetiology, pathology, physiology and outcome. Medicine, 2016, 44, 305-309.	0.4	0
156	Differences in systemic adaptive immunity contribute to the "frequent exacerbator" COPD phenotype. Respiratory Research, 2016, 17, 140.	3.6	22
157	Precision Medicine in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 593-594.	5.6	7
158	Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. European Respiratory Journal, 2016, 47, 186-193.	6.7	393
159	Deficiency Mutations of Alpha-1 Antitrypsin. Effects on Folding, Function, and Polymerization. American Journal of Respiratory Cell and Molecular Biology, 2016, 54, 71-80.	2.9	31
160	The use of whole-exome sequencing to disentangle complex phenotypes. European Journal of Human Genetics, 2016, 24, 298-301.	2.8	15
161	Validation of the Recording of Acute Exacerbations of COPD in UK Primary Care Electronic Healthcare Records. PLoS ONE, 2016, 11, e0151357.	2.5	117
162	Role of a functional polymorphism in the F2R gene promoter in sarcoidosis. Respiriology, 2015, 20, 1285-1287.	2.3	5

#	ARTICLE	IF	CITATIONS
163	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Review</i> , 2015, 24, 159-172.	7.1	72
164	Republished: Lung consequences in adults born prematurely. <i>Postgraduate Medical Journal</i> , 2015, 91, 712-718.	1.8	17
165	Lung function, symptoms and inflammation during exacerbations of non-cystic fibrosis bronchiectasis: a prospective observational cohort study. <i>Respiratory Research</i> , 2015, 16, 16.	3.6	60
166	Lung consequences in adults born prematurely. <i>Thorax</i> , 2015, 70, 574-580.	5.6	109
167	Lung disease in primary antibody deficiency. <i>Lancet Respiratory Medicine</i> , 2015, 3, 651-660.	10.7	92
168	COPD and bronchiectasis overlap syndrome. <i>European Respiratory Journal</i> , 2015, 45, 310-313.	6.7	139
169	Hospitalized Exacerbations of COPD. <i>Chest</i> , 2015, 147, 999-1007.	0.8	269
170	An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, e4-e27.	5.6	166
171	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Journal</i> , 2015, 45, 879-905.	6.7	138
172	Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. <i>Thorax</i> , 2015, 70, 930-938.	5.6	61
173	Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2015, 109, 1147-1154.	2.9	40
174	Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD). <i>BMJ Open</i> , 2014, 4, e005540-e005540.	1.9	203
175	Microbial dysbiosis in bronchiectasis. <i>Lancet Respiratory Medicine</i> , 2014, 2, 945-947.	10.7	9
176	Activity, Severity and Impact of Respiratory Disease in Primary Antibody Deficiency Syndromes. <i>Journal of Clinical Immunology</i> , 2014, 34, 68-75.	3.8	34
177	Impact of a functional polymorphism in the PAR-1 gene promoter in COPD and COPD exacerbations. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2014, 307, L311-L316.	2.9	12
178	Neither anti-inflammatory nor antibiotic treatment significantly shortens duration of cough in acute bronchitis compared with placebo. <i>Evidence-Based Medicine</i> , 2014, 19, 98-98.	0.6	1
179	How to assess the severity of bronchiectasis. <i>European Respiratory Journal</i> , 2014, 43, 1217-1219.	6.7	14
180	Multi-scale Analysis of Imaging Features and Its Use in the Study of COPD Exacerbation Susceptible Phenotypes. <i>Lecture Notes in Computer Science</i> , 2014, 17, 417-424.	1.3	2

#	ARTICLE	IF	CITATIONS
181	COPD Exacerbations. Immunology and Allergy Clinics of North America, 2013, 33, 95-115.	1.9	42
182	Factors associated with change in exacerbation frequency in COPD. Respiratory Research, 2013, 14, 79.	3.6	58
183	Cardiovascular Risk, Myocardial Injury, and Exacerbations of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1091-1099.	5.6	134
184	Gastro-oesophageal reflux disease and COPD. , 2013, , 105-116.		1
185	Time course and pattern of COPD exacerbation onset. Thorax, 2012, 67, 238-243.	5.6	139
186	Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to Evaluate Severity of COPD Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1218-1224.	5.6	164
187	Dose response of continuous positive airway pressure on nasal symptoms, obstruction and inflammation<i>in vivo</i>and<i>in vitro</i>. European Respiratory Journal, 2012, 40, 1180-1190.	6.7	16
188	Detrended fluctuation analysis of peak expiratory flow and exacerbation frequency in COPD. European Respiratory Journal, 2012, 40, 1123-1129.	6.7	24
189	Phenotype-based Care in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 935-936.	5.6	3
190	Are early life factors considered when managing respiratory disease? A British Thoracic Society survey of current practice: TableÂ1. Thorax, 2012, 67, 1110-1110.	5.6	42
191	COPD Exacerbations. Medical Clinics of North America, 2012, 96, 789-809.	2.5	35
192	Management of Exacerbations in Chronic Obstructive Pulmonary Disease. , 2012, , 562-567.		0
193	The Impact of Ischemic Heart Disease on Symptoms, Health Status, and Exacerbations in Patients With COPD. Chest, 2012, 141, 851-857.	0.8	89
194	25-hydroxyvitamin D deficiency, exacerbation frequency and human rhinovirus exacerbations in chronic obstructive pulmonary disease. BMC Pulmonary Medicine, 2012, 12, 28.	2.0	47
195	Chronic obstructive pulmonary disease: aetiology, pathology, physiology and outcome. Medicine, 2012, 40, 257-261.	0.4	1
196	Intersession repeatability of a novel nasal lavage technique. Translational Research, 2011, 158, 163-168.	5.0	4
197	SERPINA1 11478G->A variant, serum Â1-antitrypsin, exacerbation frequency and FEV1 decline in COPD. Thorax, 2011, 66, 418-424.	5.6	9
198	Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art. Expert Review of Respiratory Medicine, 2011, 5, 647-662.	2.5	128

#	ARTICLE	IF	CITATIONS
199	Exacerbation Phenotyping in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 625-626.	5.6	33
200	Temporal Clustering of Exacerbations in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 985-985.	5.6	1
201	Serum IP-10 as a Biomarker of Human Rhinovirus Infection at Exacerbation of COPD. Chest, 2010, 137, 812-822.	0.8	101
202	Use and utility of a 24-hour Telephone Support Service for "high risk"™ patients with COPD. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2010, 19, 260-265.	2.3	18
203	Domiciliary pulse-oximetry at exacerbation of chronic obstructive pulmonary disease: prospective pilot study. BMC Pulmonary Medicine, 2010, 10, 52.	2.0	78
204	The Potential Value of Biomarkers in Diagnosis and Staging of COPD and Exacerbations. Seminars in Respiratory and Critical Care Medicine, 2010, 31, 267-275.	2.1	21
205	Increased Risk of Myocardial Infarction and Stroke Following Exacerbation of COPD. Chest, 2010, 137, 1091-1097.	0.8	398
206	Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2010, 363, 1128-1138.	27.0	2,359
207	The rhythm of chronic obstructive pulmonary disease exacerbations. Journal of Clinical Epidemiology, 2010, 63, 1285-1286.	5.0	5
208	Exacerbation rate, health status and mortality in COPD – a review of potential interventions. International Journal of COPD, 2009, 4, 203.	2.3	156
209	Temporal Clustering of Exacerbations in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 369-374.	5.6	231
210	Management and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art review. BMC Medicine, 2009, 7, 40.	5.5	44
211	Determinants and impact of fatigue in patients with chronic obstructive pulmonary disease. Respiratory Medicine, 2009, 103, 216-223.	2.9	107
212	An introduction to conducting COPD exacerbation research. Respiratory Medicine: COPD Update, 2009, 5, 38-44.	0.0	1
213	"Temporal Clustering" of COPD Exacerbations May Reflect Corticosteroid Withdrawal. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 483-483.	5.6	0
214	Frequent Exacerbators in COPD: Who Are They?. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 284-284.	5.6	0
215	Long-term Erythromycin Therapy Is Associated with Decreased Chronic Obstructive Pulmonary Disease Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 1139-1147.	5.6	384
216	Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. , 2008, , 517-521.		0

#	ARTICLE	IF	CITATIONS
217	Structural and Functional Co-conspirators in Chronic Obstructive Pulmonary Disease Exacerbations. Proceedings of the American Thoracic Society, 2007, 4, 602-605.	3.5	21
218	Changes to letters in Thorax. Thorax, 2007, 62, 474-474.	5.6	0
219	Mechanism of Statin-Associated Mortality Reduction in COPD. Chest, 2007, 132, 1409.	0.8	10
220	The Biology of a Chronic Obstructive Pulmonary Disease Exacerbation. Clinics in Chest Medicine, 2007, 28, 525-536.	2.1	31
221	Use of Plasma Biomarkers at Exacerbation of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2006, 174, 867-874.	5.6	391
222	Effect of Interactions Between Lower Airway Bacterial and Rhinoviral Infection in Exacerbations of COPD. Chest, 2006, 129, 317-324.	0.8	288
223	Nasal symptoms, airway obstruction and disease severity in chronic obstructive pulmonary disease. Clinical Physiology and Functional Imaging, 2006, 26, 251-256.	1.2	31
224	Systemic and Upper and Lower Airway Inflammation at Exacerbation of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 71-78.	5.6	304
225	Airway and Systemic Inflammation and Decline in Lung Function in Patients With COPD. Chest, 2005, 128, 1995-2004.	0.8	404
226	Early Therapy in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 292-292.	5.6	0
227	Exacerbations and Time Spent Outdoors in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 446-452.	5.6	267
228	Relationships Among Bacteria, Upper Airway, Lower Airway, and Systemic Inflammation in COPD<xref rid="AFF1">[*]</xref>. Chest, 2005, 127, 1219.	0.8	101
229	Early Therapy Improves Outcomes of Exacerbations of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 1298-1303.	5.6	596
230	Upper airway symptoms and quality of life in chronic obstructive pulmonary disease (COPD). Respiratory Medicine, 2004, 98, 767-770.	2.9	66
231	Patient pathway modelling using discrete event simulation to improve the management of COPD. Journal of the Operational Research Society, 0, , 1-25.	3.4	1
232	The nose and sinuses in COPD. , 0, , 138-147.		1
233	COPD: definition, severity and impact of pulmonary exacerbations. , 0, , 13-24.		0
234	Primary immunodeficiency. , 0, , 153-166.		0

#	ARTICLE	IF	CITATIONS
235	CONQUEST: A Quality Improvement Program for Defining and Optimizing Standards of Care for Modifiable High-Risk COPD Patients. Patient Related Outcome Measures, 0, Volume 13, 53-68.	1.2	3